Abstracts tagged "epidemiologic methods and spondylarthropathy"

Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting
The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis
Michael J. Nissen¹, Adrian Ciurea², Juerg Bernhard³, Rudiger Muller⁴, Giorgio Tamborrini⁵, Martin Toniolo⁶, Cem Gabay⁷ and Axel Finckh¹, ¹Rheumatology, Geneva University Hospital, Geneva, Switzerland, ²Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, ³Rheumatology, Solothurn Hospital, Solothurn, Switzerland, ⁴Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁵Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, ⁶Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, ⁷University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland
Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
Abstract Number: 584 • 2014 ACR/ARHP Annual Meeting
Flare in Spondyloarthritis: Proposal of a Meaningful Change in Symptomatic Outcome Measures in Axial Spondyloarthritis
Maxime Dougados¹, Emily Wood², Laure Gossec³, Désirée van der Heijde⁴ and Isabelle Logeart⁵, ¹Université Paris René Descartes and Hôpital Cochin, Paris, France, ²Biostatistics, Quanticate, Hitchin, England, ³Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Pfizer, Paris, France
Background/Purpose: Recognition of flare is important in both daily practice and clinical trial setting. However, there is no clear definition of flare in patients with…
Abstract Number: 540 • 2014 ACR/ARHP Annual Meeting
Two Years Sacroiliac Radiographic Progression Rate and Influence of Baseline Markers of Inflammation in Recent Onset Spondyloarthritis
Maxime Dougados¹, Christophe Demattei², Rosaline van den Berg³, Viet Vo Hoang⁴, Fabrice Thévenin⁵, Monique Reijnierse⁶, Damien Loeuille⁷, Antoine Feydy⁸, Pascal Claudepierre⁹ and Désirée van der Heijde¹⁰, ¹INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ²Service BESPIM, CHU, Nimes, France, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of radiology, Lyon, France, ⁵Radiology B, Paris Descartes University, Côchin Hospital, APHP, Paris, France, ⁶Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rhumatology, CHU Nancy, Vandoeuvre Les Nancy, France, ⁸Paris Descartes University, Radiology B department, Cochin Hospital, paris, France, ⁹Rheumatology, Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, ¹⁰LUMC, Leiden, Netherlands
Background/Purpose: According to the ASAS axial spondyloarthritis (SpA) criteria, patients suffering from inflammatory back pain (IBP) can be recognized as suffering from axial SpA even…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].